Oligonucleotide Synthesis Market by Product ((Drugs (ASO, siRNA), Synthesized Oligos (Product (Primers, Probes)), Type ((Custom, Predesigned), Reagents, Equipment), Application (Therapeutic (Rare Diseases), Research, Diagnostics) - Global Forecast to 2030

icon1
USD 24.70 BN
MARKET SIZE, 2030
icon2
CAGR 18.6%
(2025-2030)
icon3
456
REPORT PAGES
icon4
568
MARKET TABLES

OVERVIEW

oligonucleotide-synthesis-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The oligonucleotide synthesis market is projected to reach USD 24.70 billion by 2030 from USD 10.50 billion in 2025 at a CAGR of 18.6% during the forecast period. The major factors driving the growth of this market include the increasing use of synthesized oligos for therapeutic & diagnostic applications, technological advancements in oligonucleotide synthesis, growing government investments in life science research and synthetic biolog, and the growing focus on precision/personalized medicine.

KEY TAKEAWAYS

  • BY REGION
    The North America oligonucleotide synthesis market dominated, with a share of 45.4% in 2024. The presence of several global players and the growing research activities for the development of oligonucleotide-based therapeutics, are some factors supporting the growth of the North American market.
  • BY PRODUCTS
    By products, the oligonucleotide-based drugs segment accounted for the largest share of 66.8% of the market in 2024. This dominance can primarily be attributed to the increasing number of FDA-approved drugs and the growing clinical pipeline of oligonucleotide-based drugs.
  • BY APPLICATION
    By application, the therapeutic applications segment is expected to register the highest CAGR of 19.7%, owing to the increasing use of oligonucleotides as therapeutic agents, such as antisense oligos (ASOs) and siRNAs, for treating neurological & rare diseases.
  • BY END USER
    By end user, the hospitals segment is expected to grow at the fastest rate, owing to the increasing FDA approvals for oligonucleotide-based drugs, increasing awareness about alternative therapies and the growing investments in healthcare spending.
  • COMPETITIVE LANDSCAPE
    Major players in the global oligonucleotide synthesis market, such as Danaher Corporation, Thermo Fisher Scientific Inc., Merck KGaA, among others have employed various strategies to expand their global footprints and increase their market shares such as product launches, expansions, acquisitions, partnerships, and collaborations.

The oligonucleotide synthesis market is witnessing steady growth, propelled by rising demand for therapeutic oligos (siRNA, ASO, mRNA adapters, CRISPR guides) and clinical-grade GMP manufacturing. Growth is also driven by routine use in qPCR/NGS library prep, companion diagnostics, and synthetic biology (gene circuits, DNA data storage, pooled screens). Buyers prioritize fast turnaround, high purity, and scalable QC (HPLC/UPLC, LC–MS) as programs move from research to IND/BLA.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

While customer demand in the broader healthcare landscape is shifting from traditional chemical-based therapies to advanced biotechnology-based treatments, this evolution creates new revenue opportunities for players in the oligonucleotide synthesis market. Emerging therapeutic areas such as genetic disorders, rare diseases, oncolog, urology, infectious diseases, neurology, and cardiovascular diseases drive demand for oligonucleotide-based solutions. Additionally, adjacent markets—including gene therapy, metagenomic sequencing, biosimilars, therapeutic vaccines, peptides and therapeutic proteins, and RNA therapeutics—are opening as lucrative avenues for growth.

oligonucleotide-synthesis-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Increasing use of synthesized oligos in therapeutic & diagnostic applications
  • Growing government investments in life science research and synthetic biology
RESTRAINTS
Impact
Level
  • Complexities associated with therapeutic oligonucleotides
OPPORTUNITIES
Impact
Level
  • Increasing R&D investments by key players in emerging economies
CHALLENGES
Impact
Level
  • Lack of standard regulations
  • Delivery of oligonucleotide drugs to specific targets

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Increasing use of synthesized oligos in therapeutic & diagnostic applications

The key driver of the rapid growth in the oligonucleotide market is the increasing potential for oligonucleotide-based drugs to treat a wide range of neurological disorders and orphan diseases. The rising regulatory approvals for these emerging therapies underscore their proven safety and effectiveness, boosting market confidence. A robust clinical pipeline further enhances the prospects for ongoing improvements and the launch of new products. Beyond therapeutic uses, oligonucleotides play a crucial role in applications such as microarrays, molecular diagnostics, genetic testing, and gene therapy, showcasing their versatility.

Restraint: Complexities associated with therapeutic oligonucleotides

One of the challenges in oligonucleotide synthesis is maintaining precise control over the length and structure of the therapeutic oligonucleotides while minimizing impurities. The process requires high precision and uniformity to meet the rigorous quality standards of regulatory authorities. However, these challenges become significantly more complex as the size and intricacy of the oligonucleotides increase. Another critical issue is the large amount of waste generated during the synthesis process. Many of the nucleotides used are not incorporated into the final target sequences, resulting in wasted materials. This creates harmful chemical waste, posing environmental concerns and increasing production costs.

Opportunity: Increasing R&D investments by key players in emerging economies

China, India, Japan, Brazil, and Argentina present significant growth opportunities for the oligonucleotide synthesis market. This growth is driven by increasing interest in biotechnology, the development of healthcare infrastructure in these countries, and substantial investments in research and development from major pharmaceutical and biotechnology companies. The Latin America and Asia Pacific regions are lucrative growth opportunities for global players aiming to expand market presence.

Challenge: Delivery of oligonucleotide drugs to specific targets

One of the significant challenges in delivering oligonucleotide-based medications is the inefficiency associated with conventional methods, particularly intravenous (IV) delivery. This inefficiency makes it challenging to administer antisense oligonucleotide (ASO)--based drugs in sufficient quantities to target tissues, compromising treatment effectiveness and potentially leading to unpredictable clinical responses. Another significant obstacle comes from the physicochemical properties of the oligonucleotides themselves. Due to their large size and negative charge, these molecules struggle to cross biological barriers, such as the blood-brain barrier (BBB).

oligonucleotide-synthesis-market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Used pooled synthetic oligonucleotide libraries (Twist Oligo Pools) to encode large, diverse protein-sequence sets for high-throughput folding/function screens. Enabled rapid construction of thousands of designs| Reduced false positives from in-silico models | Experimental feedback improved computational tools.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The oligonucleotide synthesis market operates within a multi-tiered ecosystem spanning raw-material suppliers, oligonucleotide manufacturers, end users, and regulatory bodies. At the base are equipment, reagents, and consumables manufacturers, whose instruments and proprietary chemistries enable high-precision strand assembly. Upstream, pharmaceutical & biotechnology companies, academic and research institutes, and contract research and development organizations translate these capabilities into next-generation therapeutics. Hospitals and diagnostic centers are critical end users, validating safety and efficacy in diverse patient populations. Oversight by regulatory authorities ensures that each component of this tightly interconnected value chain meets rigorous quality, safety, and performance standards.

oligonucleotide-synthesis-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

oligonucleotide-synthesis-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Oligonucleotide Synthesis Market, By Product

In 2024, the oligonucleotide-based drugs segment held the largest share of the market. This segment is also expected to be the fastest-growing segment in the market. The major factors driving the growth of this segment are the increasing number of regulatory approvals received for oligonucleotide-based drugs, increasing research focus on the development of oligonucleotide-based drugs, and a shifting focus on developing innovator oligonucleotide-based drugs against common indications such as cardiovascular diseases.

Oligonucleotide Synthesis Market, By Application

In 2024, the therapeutic applications segment held the largest share of the market. Oligonucleotide-based therapies are increasingly used treatment for rare diseases. These therapies consist of shott sequences of DNA or RNA that are highly specific and have a strong affinity for target molecules. By modifying the expression of genes involved in various disease pathways, these therapies offer a promising solution for treating diseases, including cancer, asthma, and diabetes.

Oligonucleotide Synthesis Market, By Product

The hospitals segment accounted for the largest share of the oligonucleotide synthesis market in 2024. The demand for oligonucleotide drugs in hospitals is due to the large number of patients seeking treatment for various conditions. These drugs are used to treat patients suffering from diseases such as Transthyretin Amyloidosis (ATTR), Duchenne Muscular Dystrophy (DMD), Spinal Muscular Atrophy (SMA), and Hepatic Veno-occlusive Disease (VOD).

REGION

North America to be fastest-growing region in global oligonucleotide synthesis market during forecast period

The North America oligonucleotide synthesis market is expected to register the highest CAGR during the forecast period, driven by significant investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. This has led to continuous advancements in oligonucleotide therapies. The early adoption of emerging technologies and alternative therapies, backed by a strong venture capital ecosystem, supports market growth.

oligonucleotide-synthesis-market Region

oligonucleotide-synthesis-market: COMPANY EVALUATION MATRIX

In the oligonucleotide synthesis market matrix, Danaher Corporation (Star) leads with its broad DNA/RNA portfolio from research to GMP-grade supply, global footprint, and integration with Danaher’s automation/analytics deliver scale, quality, and fast turnaround across diagnostics, therapeutics, and synthetic biology. Maravai LifeSciences (Emerging Leader) rapidly expanding GMP oligo and modified-nucleotide capacity, leveraging CleanCap mRNA technology and CDMO services; as clinical oligo and mRNA/siRNA programs grow, Maravai is well positioned to advance toward the leaders’ quadrant.

oligonucleotide-synthesis-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2024 (Value) USD 8.87 Billion
Market Forecast in 2030 (Value) USD 24.70 Billion
Growth Rate CAGR of 18.6% from 2025-2030
Years Considered 2023-2030
Base Year 2024
Forecast Period 2025-2030
Units Considered Value (USD Billion)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Product:
    • oligonucleotide-based drugs
    • synthesized oligonucleotide
    • reagents & consumables
    • equipment
  • By Application:
    • therapeutic applications
    • research applications
    • diagnostic applications
  • End User:
    • hospitals
    • pharmaceutical & biotechnology companies
    • diagnostic laboratories
    • CROs & CMOs
    • academic & research institutes
Regions Covered North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

WHAT IS IN IT FOR YOU: oligonucleotide-synthesis-market REPORT CONTENT GUIDE

oligonucleotide-synthesis-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Competitive Benchmarking of Key Players Comparative profiling of major market participants covering business overview, product portfolios, pricing strategies, technological capabilities, and regional presence. Provides insights on competitor positioning and supports differentiation strategies.
End-user Mapping and Opportunity Assessment Identification and profiling of key end users including pharmaceutical & biotech companies, academic institutes, and CROs across high-growth regions. Aids in customer targeting, partnership identification, and business expansion planning.

RECENT DEVELOPMENTS

  • July 2025 : AstraZeneca plans to invest USD 50 billion in the U.S. by 2030 to expand medicines R&D and manufacturing, including a new large drug-substance facility in Virginia that will produce small molecules, peptides, and oligonucleotides.
  • February 2025 : Astellas Pharma Inc. (Japan) announced that the US FDA approved expanded US Prescribing information for IZERVAY for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As a result, IZERVAY was approved without limiting the duration of dosing.
  • February 2025 : Biogen (US) and Stoke Therapeutics (US) announced a collaboration for the development and commercialization of zorevunersen, an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene for the treatment of Dravet syndrome.

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
43
RESEARCH METHODOLOGY
48
EXECUTIVE SUMMARY
61
PREMIUM INSIGHTS
64
MARKET OVERVIEW
This Section Covers the Market Dynamics, and Upcoming Trends Shaping the Oligonucleotide Synthesis Market.
67
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increasing use of synthesized oligos in therapeutic & diagnostic applications
    - Technological advancements
    - Growing government investments in life science research & synthetic biology
    - Growing focus on precision/personalized medicine
    RESTRAINTS
    - Complexities associated with therapeutic oligonucleotides
    OPPORTUNITIES
    - Increasing R&D investments by key players in emerging economies
    CHALLENGES
    - Lack of standard regulations
    - Delivery of oligonucleotide drugs to specific targets
  • 5.3 INDUSTRY TRENDS
    GROWING FOCUS ON DEVELOPMENT OF DRUG DELIVERY TECHNOLOGIES FOR OLIGONUCLEOTIDE-BASED DRUGS
    GROWING FOCUS ON TECHNOLOGY DEVELOPMENT FOR SUSTAINABLE & LARGE-SCALE SYNTHESIS OF OLIGONUCLEOTIDES
    FOCUS ON ACQUISITIONS TO ENHANCE MARKET POSITION
    GROWING USE OF ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS FOR TREATMENT OF NEUROLOGICAL & RARE DISEASES
  • 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
    ROLE IN ECOSYSTEM
  • 5.7 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Solid-phase synthesis
    - Liquid-phase synthesis
    - Enzymatic oligo synthesis
    COMPLEMENTARY TECHNOLOGIES
    - Polymerase chain reaction (PCR)
    - Next-generation sequencing
    - Microarray analysis
    ADJACENT TECHNOLOGIES
    - CRISPR
    - Lipid nanoparticles
  • 5.8 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2022−2024
    AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, 2022−2024
    AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYERS, 2022−2024
    AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY REGION, 2024
    AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2024
    AVERAGE PRICING TREND OF OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2024
  • 5.9 PATENT ANALYSIS
    PATENTS FILED, BY DOCUMENT TYPE, 2014–2024
  • 5.10 PIPELINE ANALYSIS
  • 5.11 TRADE ANALYSIS
    IMPORT DATA (HS CODE 293499)
    EXPORT DATA (HS CODE 293499)
  • 5.12 KEY CONFERENCES & EVENTS, 2025–2026
  • 5.13 TARIFF & REGULATORY LANDSCAPE
    TARIFF DATA (HS CODE 2934.99, 3822.00)
    - Trade policy updates affecting oligonucleotide synthesis market, 2022−2025
    - Impact of Tariffs on pricing & supply chain
    REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
    REGULATORY FRAMEWORK
  • 5.14 PORTER’S FIVE FORCES ANALYSIS
    DEGREE OF COMPETITION
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF SUBSTITUTES
    THREAT OF NEW ENTRANTS
  • 5.15 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA FOR END USERS
  • 5.16 CASE STUDY ANALYSIS
    CASE STUDY 1: THERMO FISHER SCIENTIFIC LEVERAGED ITS OLIGONUCLEOTIDE SYNTHESIS EXPERTISE TO DELIVER LARGE-SCALE DYE-LABELED OLIGONUCLEOTIDES TO ITS CLIENT
    CASE STUDY 2: BAKER LAB UTILIZING TWIST BIOSCIENCES OLIGO POOLS FOR EVALUATING PROTEIN FOLDING
    CASE STUDY 3: ENHANCED MOTOR FUNCTION WITH SPINRAZA TREATMENT IN ADOLESCENTS WITH LATE-ONSET SMA
  • 5.17 INVESTMENT/FUNDING SCENARIO
  • 5.18 IMPACT OF GENERATIVE AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET
  • 5.19 TRUMP TARIFF IMPACT OVERVIEW: OLIGONUCLEOTIDE SYNTHESIS MARKET
    KEY TARIFF RATES
    PRICE IMPACT ANALYSIS
    KEY IMPACT ON VARIOUS REGIONS
    - US
    - Europe
    - APAC
    - Rest of the World
    END-USE INDUSTRY IMPACT
    - Hospitals
    - Pharmaceutical & biotechnology companies
    - Diagnostic laboratories
    - CROs & CDMOs
    - Academic & research institutes
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT
Market Assessment for Oligonucleotide Synthesis Market, By Product: Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
124
  • 6.1 INTRODUCTION
  • 6.2 OLIGONUCLEOTIDE-BASED DRUGS
    OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE
    - Antisense oligonucleotide-based drugs
    - siRNA oligonucleotide-based drugs
    - Other oligonucleotide-based drugs
  • 6.3 SYNTHESIZED OLIGONUCLEOTIDES
    SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT
    - Primers
    - Probes
    - DNA oligonucleotides
    - RNA oligonucleotides
    - Other synthesized oligonucleotides
    SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
    - Custom oligonucleotides
    - Predesigned oligonucleotides
  • 6.4 REAGENTS & CONSUMABLES
    GROWING DEMAND FOR OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO DRIVE MARKET GROWTH FOR REAGENTS
  • 6.5 EQUIPMENT
    TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO DRIVE GROWTH IN EQUIPMENT MARKET
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION
Market Assessment for Oligonucleotide Synthesis Market, By Application: Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
174
  • 7.1 INTRODUCTION
  • 7.2 THERAPEUTIC APPLICATIONS
    THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE
    - Neurological disorders
    - Rare diseases
    - Other diseases
  • 7.3 RESEARCH APPLICATIONS
    PCR
    - Increasing use of PCR in molecular biology research to drive market
    SEQUENCING
    - Advancements in sequencing technologies & low cost of DNA sequencing to boost market
    OTHER RESEARCH APPLICATIONS
  • 7.4 DIAGNOSTIC APPLICATIONS
    INCREASING DEMAND FOR RAPID & SPECIFIC METHODS FOR DISEASE DETECTION SUPPORT MARKET GROWTH
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER
Market Assessment for Oligonucleotide Synthesis Market, By End User: Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
205
  • 8.1 INTRODUCTION
  • 8.2 HOSPITALS
    INCREASING FDA APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS FOR RARE DISEASES TO DRIVE MARKET
  • 8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO PROPEL MARKET
  • 8.4 DIAGNOSTIC LABORATORIES
    RISING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO FUEL MARKET
  • 8.5 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
    WIDE RANGE OF CUSTOMIZED OLIGO SERVICES TO SUPPORT MARKET GROWTH
  • 8.6 ACADEMIC RESEARCH INSTITUTES
    GROWING USE OF OLIGOS FOR GENOMIC RESEARCH APPLICATIONS TO PROPEL MARKET
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION
Market Assessment for Oligonucleotide Synthesis Market, By Region & Country: Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
224
  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    NORTH AMERICA: MACROECONOMIC OUTLOOK
    US
    - Government initiatives and strategic developments by leading players to drive market
    CANADA
    - Strong research infrastructure and availability of funding to support market growth
  • 9.3 EUROPE
    EUROPE: MACROECONOMIC OUTLOOK
    GERMANY
    - Government & private funding investments towards health research to drive market
    UK
    - Strategic collaborations & partnerships between key market players to fuel market
    FRANCE
    - Favorable government initiatives for genomics research to boost demand
    ITALY
    - Increasing R&D expenditure for pharma & biotech companies to support market growth
    SPAIN
    - Favorable funding investments for biomedical research to drive market
    REST OF EUROPE
  • 9.4 ASIA PACIFIC
    ASIA PACIFIC: MACROECONOMIC OUTLOOK
    CHINA
    - Expansion of leading pharmaceutical & biotechnology companies to drive market
    JAPAN
    - Growing research initiatives & strategic developments to boost demand
    INDIA
    - Development of bioclusters and improvements in healthcare infrastructure to propel market
    AUSTRALIA
    - Increasing government initiatives and research funding to support market growth
    SOUTH KOREA
    - Growing research activities and strategic expansions in oligonucleotide synthesis to aid market
    REST OF ASIA PACIFIC
  • 9.5 LATIN AMERICA
    LATIN AMERICA: MACROECONOMIC OUTLOOK
    BRAZIL
    - Availability of leading oligo-based therapies to support market growth
    MEXICO
    - Growing adoption of NGS technology to drive market
    ARGENTINA
    - Increasing research collaborations and government support to boost market
    REST OF LATIN AMERICA
  • 9.6 MIDDLE EAST
    MIDDLE EAST: MACROECONOMIC OUTLOOK
    GCC COUNTRIES
    - Saudi Arabia (KSA)
    - United Arab Emirates (UAE)
    - Other GCC countries
    REST OF MIDDLE EAST
  • 9.7 AFRICA
    IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
    AFRICA: MACROECONOMIC OUTLOOK
COMPETITIVE LANDSCAPE
This Section Covers Strategic Analysis of Key Players, Market Shares (%), Revenue Analysis (USD Million), Competitive Mapping and Benchmarking for Key Players and SMEs/Start-ups
331
  • 10.1 INTRODUCTION
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 10.3 REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS)
    REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022−2024
    REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS), 2022−2024
  • 10.4 MARKET SHARE ANALYSIS
    MARKET SHARE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
    MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS),2024
  • 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
  • 10.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT:
    - Company footprint (Research & diagnostic applications)
    - Region footprint (Research & diagnostic applications)
    - Product footprint (Research & diagnostic applications)
    - Application footprint (Research & diagnostic applications)
    - Company footprint (Therapeutic applications)
    - Region footprint (Therapeutic applications)
    - Product footprint (Therapeutic applications)
    - Application footprint (Therapeutic applications)
  • 10.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    - Detailed list of key startups/SMEs
    - Competitive benchmarking of startups/SMEs
  • 10.8 COMPANY VALUATION & FINANCIAL METRICS
    FINANCIAL METRICS (RESEARCH & DIAGNOSTIC APPLICATIONS)
    COMPANY VALUATION (RESEARCH & DIAGNOSTIC APPLICATIONS)
    FINANCIAL METRICS (THERAPEUTIC APPLICATIONS)
    COMPANY VALUATION (THERAPEUTIC APPLICATIONS)
  • 10.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
    BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (RESEARCH & DIAGNOSTIC APPLICATIONS)
    BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (THERAPEUTIC APPLICATIONS)
  • 10.10 COMPETITIVE SCENARIO
    PRODUCT APPROVALS
COMPANY PROFILES
In-depth Profiling of Key Players and SMEs/Start-ups Operating in the Oligonucleotide Synthesis Market (For Research & Diagnostic Applications as well as Therapeutic Applications): Business Overview, Offerings, Recent Developme
360
  • 11.1 KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS)
    DANAHER CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    MERCK KGAA
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    LGC LIMITED
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    EUROFINS SCIENTIFIC
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    AGILENT TECHNOLOGIES, INC.
    - Business overview
    - Products offered
    - Recent developments
    KANEKA CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    MARAVAI LIFESCIENCES
    - Business overview
    - Products offered
    - Recent developments
    AZENTA US INC.
    - Business overview
    - Products offered
    TWIST BIOSCIENCE
    - Business overview
    - Products offered
    - Recent developments
    GENSCRIPT
    - Business overview
    - Products offered
    - Recent developments
  • 11.2 KEY PLAYERS (THERAPEUTIC APPLICATIONS)
    BIOGEN
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    ALNYLAM PHARMACEUTICALS, INC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    SAREPTA THERAPEUTICS, INC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    ASTRAZENECA
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    ASTELLAS PHARMA INC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    JAZZ PHARMACEUTICALS PLC
    - Business overview
    - Products offered
    NIPPON SHINYAKU, CO. LTD.
    - Business overview
    - Products offered
    - Recent developments
    IONIS PHARMACEUTICALS, INC.
    - Business overview
    - Products offered
    - Recent developments
    NOVARTIS AG
    - Business overview
    - Products offered
    - Recent developments
  • 11.3 OTHER PLAYERS
    OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S)
    BIOLEGIO B.V.
    BIOLYTIC LAB PERFORMANCE, INC.
    BIOCOMMA LIMITED
    REVVITY (SUBSIDIARY OF HORIZON DISCOVERY LTD.)
    BIO-SYNTHESIS, INC.
    CREATIVE BIOGENE
    REPROCELL INC. (THROUGH SUBSIDIARY BIOSERVE)
APPENDIX
448
  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
  • TABLE 2 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES (2016−2025)
  • TABLE 3 LIST OF ACQUISITIONS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
  • TABLE 4 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS
  • TABLE 5 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2022−2024
  • TABLE 6 AVERAGE SELLING PRICE TREND FOR OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYERS, 2022-2024
  • TABLE 7 AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY REGION, 2024
  • TABLE 8 AVERAGE SELLING PRICE FOR OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2024
  • TABLE 9 INDICATIVE LIST OF PATENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
  • TABLE 10 IMPORT VALUE OF HS CODE 293499-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)
  • TABLE 11 IMPORT VOLUME FOR HS CODE 293499-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (TONS)
  • TABLE 12 EXPORT VALUE OF HS CODE 293499-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)
  • TABLE 13 EXPORT VOLUME FOR HS CODE 9027-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (TONS)S
  • TABLE 14 OLIGONUCLEOTIDE SYNTHESIS MARKET: LIST OF CONFERENCES & EVENTS
  • TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 OLIGONUCLEOTIDE SYNTHESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 21 KEY COMPANIES IMPLEMENTING AI
  • TABLE 22 US ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 23 KEY PRODUCT-RELATED TARIFF: MISCELLANEOUS CHEMICAL PRODUCTS, PHARMACEUTICAL PRODUCTS, ORGANIC CHEMICALS.
  • TABLE 24 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES
  • TABLE 25 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 26 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 27 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 28 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 29 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 30 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 31 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 32 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 33 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME, BY PRODUCT, 2023–2030 (NUMBER OF VIALS)
  • TABLE 34 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 35 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS
  • TABLE 36 ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 37 NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 38 EUROPE: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 39 ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 40 LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 41 MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 42 GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 43 APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS
  • TABLE 44 SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 45 NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 46 EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 47 ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 48 LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 49 MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 50 GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 51 APPROVED OTHER OLIGONUCLEOTIDE-BASED DRUGS
  • TABLE 52 OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 53 NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 54 EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 55 ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 56 LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 57 MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 58 GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 59 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 60 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 61 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 62 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 63 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 64 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 65 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 66 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 67 OLIGONUCLEOTIDE PRIMERS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 68 NORTH AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 69 EUROPE: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 70 ASIA PACIFIC: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 71 LATIN AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 72 MIDDLE EAST: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 73 GCC COUNTRIES: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 74 OLIGONUCLEOTIDE PROBES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 75 NORTH AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 76 EUROPE: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 77 ASIA PACIFIC: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 78 LATIN AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 79 MIDDLE EAST: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 80 GCC COUNTRIES: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 81 DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 82 NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 83 EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 84 ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 85 LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 86 MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 87 GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 88 RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 89 NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 90 EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 91 ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 92 LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 93 MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 94 GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 95 OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 96 NORTH AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 97 EUROPE: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 99 LATIN AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 100 MIDDLE EAST: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 101 GCC COUNTRIES: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 102 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 103 CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 104 NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 105 EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 106 ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 107 LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 108 MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 109 GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 110 PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 111 NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 112 EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 114 LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 115 MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 116 GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 117 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 118 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 119 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 121 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 122 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 123 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 124 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 125 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 126 EUROPE: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 127 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 128 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 129 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 130 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 131 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 132 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 133 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 134 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 135 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 136 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 137 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 138 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 139 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 140 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 141 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 142 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 143 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 144 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 145 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 146 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 147 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 148 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 149 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 150 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 151 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 152 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 153 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 154 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 155 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 156 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 157 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 158 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 159 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 160 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 161 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 162 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 163 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 164 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 165 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 166 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 167 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 168 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 169 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 170 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 171 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 172 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 173 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 174 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 175 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 176 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 177 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 178 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 179 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 180 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 181 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 182 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 183 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 184 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 185 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 186 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 187 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 188 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 189 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 190 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 191 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 192 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 193 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 194 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 195 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 196 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 197 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 198 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 199 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 200 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 201 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 202 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 203 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 204 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 205 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 206 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 207 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 208 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 209 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 210 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 211 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 212 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 213 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 214 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 215 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 216 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 217 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 218 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 219 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 220 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 221 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 222 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 223 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 224 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 225 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 226 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 227 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 228 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 229 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 230 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 231 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 232 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 233 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 234 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 235 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 236 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 237 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 238 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 239 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 240 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 241 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 242 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 243 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 244 US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 245 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 246 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 247 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 248 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 249 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 250 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 251 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 252 CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 253 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 254 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 255 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 256 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 257 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 258 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 259 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 260 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 261 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 262 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 263 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 264 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 265 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 266 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 267 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 268 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 269 GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 270 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 271 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 272 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 273 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 274 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 275 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 276 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 277 UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 278 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 279 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 280 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 281 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 282 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 283 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 284 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 285 FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 286 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 287 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 288 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 289 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 290 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 291 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 292 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 293 ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 294 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 295 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 296 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 297 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 298 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 299 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 300 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 301 SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 302 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 303 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 304 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 305 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 306 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 307 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 308 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 309 REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 310 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 311 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 312 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 313 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 314 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 315 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 316 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 317 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 318 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 319 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 320 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 321 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 322 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 323 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 324 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 325 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 326 CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 327 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 328 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 329 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 330 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 331 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 332 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 333 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 334 JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 335 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 336 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 337 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 338 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 339 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 340 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 341 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 342 INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 343 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 344 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 345 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 346 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 347 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 348 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 349 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 350 AUSTRALIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 351 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 352 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 353 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 354 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 355 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 356 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 357 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 358 SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 359 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 360 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 361 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 362 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 363 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 364 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 365 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 366 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 367 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 368 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 369 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 370 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 371 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 372 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 373 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 374 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 375 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 376 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 377 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 378 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 379 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 380 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 381 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 382 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 383 BRAZIL: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 384 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 385 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 386 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 387 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 388 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 389 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 390 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 391 MEXICO: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 392 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 393 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 394 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 395 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 396 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 397 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 398 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 399 ARGENTINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 400 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 401 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 402 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 403 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 404 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 405 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 406 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 407 REST OF LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 408 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 409 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 410 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 411 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 412 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 413 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 414 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 415 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 416 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 417 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 418 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 419 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 420 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 421 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 422 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 423 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 424 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 425 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 426 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 427 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 428 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 429 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 430 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 431 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 432 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 433 SAUDI ARABIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 434 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 435 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 436 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 437 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 438 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 439 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 440 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 441 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 442 UNITED ARAB EMIRATES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 443 UNITED ARAB EMIRATES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 444 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 445 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 446 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 447 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 448 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 449 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 450 OTHER GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 451 OTHER GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 452 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 453 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 454 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 455 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 456 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 457 REST OF MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 458 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 459 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 460 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 461 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 462 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 463 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 464 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 465 AFRICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 466 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 467 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 468 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 469 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
  • TABLE 470 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 471 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 472 STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022–2025
  • TABLE 473 STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS), 2022–2025
  • TABLE 474 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): DEGREE OF COMPETITION
  • TABLE 475 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): DEGREE OF COMPETITION
  • TABLE 476 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): REGIONAL FOOTPRINT
  • TABLE 477 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): PRODUCT FOOTPRINT
  • TABLE 478 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): APPLICATION FOOTPRINT
  • TABLE 479 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): REGION FOOTPRINT
  • TABLE 480 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): PRODUCT FOOTPRINT
  • TABLE 481 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): APPLICATION FOOTPRINT
  • TABLE 482 DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 483 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • TABLE 484 OLIGONUCLEOTIDE SYNTHESIS MARKET: PRODUCT APPROVALS, JANUARY 2022–MAY 2025
  • TABLE 485 OLIGONUCLEOTIDE SYNTHESIS MARKET: DEALS, JANUARY 2022-MAY 2025
  • TABLE 486 OLIGONUCLEOTIDE SYNTHESIS MARKET: EXPANSIONS, JANUARY 2022-MAY 2025
  • TABLE 487 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 488 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 489 DANAHER CORPORATION: DEALS, JANUARY 2021−MAY 2025
  • TABLE 490 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021−MAY 2025
  • TABLE 491 DANAHER CORPORATION: OTHER DEVELOPMENTS
  • TABLE 492 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 493 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 494 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021−MAY 2025
  • TABLE 495 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 496 MERCK KGAA: PRODUCTS OFFERED
  • TABLE 497 MERCK KGAA: DEALS, JANUARY 2021−MAY 2025
  • TABLE 498 MERCK KGAA: EXPANSIONS, JANUARY 2021−MAY 2025
  • TABLE 499 LGC LIMITED: COMPANY OVERVIEW
  • TABLE 500 LGC LIMITED: PRODUCTS OFFERED
  • TABLE 501 LGC LIMITED: DEALS, JANUARY 2021−MAY 2025
  • TABLE 502 LGC LIMITED: EXPANSIONS, JANUARY 2021−MAY 2025
  • TABLE 503 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 504 EUROFINS SCIENTIFIC: PRODUCTS OFFERED
  • TABLE 505 EUROFINS SCIENTIFIC: DEALS, JANUARY 2021−MAY 2025
  • TABLE 506 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2021−MAY 2025
  • TABLE 507 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 508 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
  • TABLE 509 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021−MAY 2025
  • TABLE 510 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021−MAY 2025
  • TABLE 511 KANEKA CORPORATION: COMPANY OVERVIEW
  • TABLE 512 KANEKA CORPORATION: PRODUCTS OFFERED
  • TABLE 513 KANEKA CORPORATION: EXPANSIONS, JANUARY 2021−MAY 2025
  • TABLE 514 MARAVAI LIFESCIENCES: COMPANY OVERVIEW
  • TABLE 515 MARAVAI LIFESCIENCES: PRODUCTS OFFERED
  • TABLE 516 MARAVAI LIFESCIENCES: DEALS, JANUARY 2021−MAY 2025
  • TABLE 517 MARAVAI LIFESCIENCES: EXPANSIONS, JANUARY 2021−MAY 2025
  • TABLE 518 AZENTA US INC.: COMPANY OVERVIEW
  • TABLE 519 AZENTA US INC.: PRODUCTS OFFERED
  • TABLE 520 TWIST BIOSCIENCE: COMPANY OVERVIEW
  • TABLE 521 TWIST BIOSCIENCE: PRODUCTS OFFERED
  • TABLE 522 TWIST BIOSCIENCE: DEALS, JANUARY 2021−MAY 2025
  • TABLE 523 GENSCRIPT: COMPANY OVERVIEW
  • TABLE 524 GENSCRIPT: PRODUCTS OFFERED
  • TABLE 525 GENSCRIPT: DEALS, JANUARY 2021−MAY 2025
  • TABLE 526 GENSCRIPT: EXPANSIONS, JANUARY 2021−MAY 2025
  • TABLE 527 BIOGEN: COMPANY OVERVIEW
  • TABLE 528 BIOGEN: PRODUCTS OFFERED
  • TABLE 529 BIOGEN: PRODUCT APPROVALS, JANUARY 2021−MAY 2025
  • TABLE 530 BIOGEN: DEALS, JANUARY 2021−MAY 2025
  • TABLE 531 BIOGEN: EXPANSIONS, JANUARY 2021−MAY 2025
  • TABLE 532 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
  • TABLE 533 ALNYLAM PHARMACEUTICALS, INC.: PRODUCTS OFFERED
  • TABLE 534 ALNYLAM PHARMACEUTICALS INC.: PRODUCT APPROVALS, JANUARY 2021−MAY 2025
  • TABLE 535 ALNYLAM PHARMACEUTICALS INC.: DEALS, JANUARY 2021−MAY 2025
  • TABLE 536 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
  • TABLE 537 SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED
  • TABLE 538 SAREPTA THERAPEUTICS: PRODUCT APPROVALS, JANUARY 2021−MAY 2025
  • TABLE 539 SAREPTA THERAPEUTICS: EXPANSIONS, JANUARY 2021−MAY 2025
  • TABLE 540 ASTRAZENECA: COMPANY OVERVIEW
  • TABLE 541 ASTRAZENECA: PRODUCTS OFFERED
  • TABLE 542 ASTRAZENECA: DEALS, JANUARY 2021−MAY 2025
  • TABLE 543 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2021−MAY 2025
  • TABLE 544 ASTELLAS PHARMA INC.: COMPANY OVERVIEW
  • TABLE 545 ASTELLAS PHARMA INC.: PRODUCTS OFFERED
  • TABLE 546 ASTELLAS PHARMA INC.: DEALS, JANUARY 2021−MAY 2025
  • TABLE 547 ASTELLAS PHARMA INC.: PRODUCT APPROVALS, JANUARY 2021−MAY 2025
  • TABLE 548 JAZZ PHARMACEUTICALS PLC: COMPANY OVERVIEW
  • TABLE 549 JAZZ PHARMACEUTICALS PLC: PRODUCTS OFFERED
  • TABLE 550 NIPPON SHINYAKU, CO. LTD.: COMPANY OVERVIEW
  • TABLE 551 NIPPON SHINYAKU, CO. LTD.: PRODUCTS OFFERED
  • TABLE 552 NIPPON SHINYAKU, CO. LTD.: DEALS, JANUARY 2021−MAY 2025
  • TABLE 553 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
  • TABLE 554 IONIS PHARMACEUTICALS, INC.: PRODUCTS OFFERED
  • TABLE 555 IONIS PHARMACEUTICALS, INC.: PRODUCT APPROVALS, JANUARY 2021−MAY 2025
  • TABLE 556 IONIS PHARMACEUTICALS, INC.: DEALS, JANUARY 2021−MAY 2025
  • TABLE 557 NOVARTIS AG: COMPANY OVERVIEW
  • TABLE 558 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 559 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2021−MAY 2025
  • TABLE 560 NOVARTIS AG: DEALS, JANUARY 2021−MAY 2025
  • TABLE 561 OLIGOMAKER APS: COMPANY OVERVIEW
  • TABLE 562 BIOLEGIO B.V.: COMPANY OVERVIEW
  • TABLE 563 BIOLYTIC LAB PERFORMANCE, INC.: COMPANY OVERVIEW
  • TABLE 564 BIOCOMMA LIMITED: COMPANY OVERVIEW
  • TABLE 565 REVVITY: COMPANY OVERVIEW
  • TABLE 566 BIO-SYNTHESIS, INC.: COMPANY OVERVIEW
  • TABLE 567 CREATIVE BIOGENE: COMPANY OVERVIEW
  • TABLE 568 REPROCELL INC.: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2024
  • FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1A (REVENUE SHARE ANALYSIS FOR RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
  • FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1B (REVENUE SHARE ANALYSIS FOR THERAPEUTIC APPLICATIONS), 2024
  • FIGURE 7 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION (RESEARCH & DIAGNOSTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2024
  • FIGURE 8 ILLUSTRATIVE EXAMPLE OF BIOGEN INC. (THERAPEUTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2024
  • FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS
  • FIGURE 10 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 11 CAGR PROJECTIONS: OLIGONUCLEOTIDE SYNTHESIS MARKET, 2025–2030
  • FIGURE 12 CAGR PROJECTIONS: OLIGONUCLEOTIDE-BASED DRUGS MARKET (THERAPEUTIC APPLICATIONS), 2025–2030
  • FIGURE 13 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN OLIGONUCLEOTIDE SYNTHESIS MARKET
  • FIGURE 14 DATA TRIANGULATION METHODOLOGY
  • FIGURE 15 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2024−2029 (USD MILLION)
  • FIGURE 18 GEOGRAPHIC SNAPSHOT OF OLIGONUCLEOTIDE SYNTHESIS MARKET
  • FIGURE 19 RISING DEMAND FOR SYNTHESIZED OLIGOS FOR DRUG DISCOVERY & DEVELOPMENT TO DRIVE MARKET
  • FIGURE 20 THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR MARKET SHARE IN US IN 2O24
  • FIGURE 21 OLIGONUCLEOTIDE-BASED DRUGS SEGMENT TO DOMINATE MARKET IN 2030
  • FIGURE 22 THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024
  • FIGURE 23 NORTH AMERICA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 24 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 25 REVENUE SHIFT AND NEW REVENUE POCKETS FOR OLIGONUCLEOTIDE MANUFACTURERS
  • FIGURE 26 VALUE CHAIN ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS)—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE
  • FIGURE 27 VALUE CHAIN ANALYSIS (THERAPEUTIC APPLICATIONS)—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE
  • FIGURE 28 ECOSYSTEM ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET
  • FIGURE 29 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, 2022−2024
  • FIGURE 30 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2024
  • FIGURE 31 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS (JANUARY 2014–DECEMBER 2024)
  • FIGURE 32 OLIGONUCLEOTIDE DRUGS PIPELINE, BY DISEASE
  • FIGURE 33 OLIGONUCLEOTIDE DRUGS PIPELINE, BY PHASE
  • FIGURE 34 OLIGONUCLEOTIDE DRUGS PIPELINE, BY REGION
  • FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • FIGURE 36 STAKEHOLDERS INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: HOSPITALS
  • FIGURE 37 BUYING CRITERIA OF END USERS FOR SYNTHESIZED OLIGONUCLEOTIDE PRODUCTS
  • FIGURE 38 BUYING CRITERIA OF HOSPITALS FOR SYNTHESIZED OLIGONUCLEOTIDE PRODUCTS
  • FIGURE 39 NIH FUNDING FOR OLIGONUCLEOTIDE SYNTHESIS PROJECTS, 2014–2024
  • FIGURE 40 AI USE CASES
  • FIGURE 41 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
  • FIGURE 42 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
  • FIGURE 43 OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022–2024
  • FIGURE 44 OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS), 2022–2024
  • FIGURE 45 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), BY KEY PLAYER, 2024
  • FIGURE 46 MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS), BY KEY PLAYER, 2024
  • FIGURE 47 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
  • FIGURE 48 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2024
  • FIGURE 49 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): COMPANY FOOTPRINT
  • FIGURE 50 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): COMPANY FOOTPRINT
  • FIGURE 51 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2024
  • FIGURE 52 EV/EBITDA OF KEY VENDORS (RESEARCH & DIAGNOSTIC APPLICATIONS)
  • FIGURE 53 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS (RESEARCH & DIAGNOSTIC APPLICATIONS)
  • FIGURE 54 EV/EBITDA OF KEY VENDORS (THERAPEUTIC APPLICATIONS)
  • FIGURE 55 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS (THERAPEUTIC APPLICATIONS)
  • FIGURE 56 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (RESEARCH & DIAGNOSTIC APPLICATIONS)
  • FIGURE 57 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (THERAPEUTIC APPLICATIONS)
  • FIGURE 58 DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 59 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 60 MERCK KGAA: COMPANY SNAPSHOT (2024)
  • FIGURE 61 LGC LIMITED: COMPANY SNAPSHOT (2024)
  • FIGURE 62 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)
  • FIGURE 63 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 64 KANEKA CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 65 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2024)
  • FIGURE 66 AZENTA US INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 67 TWIST BIOSCIENCE: COMPANY SNAPSHOT (2024)
  • FIGURE 68 GENSCRIPT: COMPANY SNAPSHOT (2024)
  • FIGURE 69 BIOGEN: COMPANY SNAPSHOT (2024)
  • FIGURE 70 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 71 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2024)
  • FIGURE 72 ASTRAZENECA: COMPANY SNAPSHOT (2024)
  • FIGURE 73 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 74 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2024)
  • FIGURE 75 NIPPON SHINYAKU, CO. LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 76 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 77 NOVARTIS AG: COMPANY SNAPSHOT (2024)

Methodology

This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global oligonucleotide synthesis market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used primarily to identify & collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, World Health Organization (WHO), United States Food and Drug Administration (US FDA), National Center for Biotechnology Information (NCBI), Industry Association of Synthetic Biology (IASB), Biotechnology Innovation Organization (BIO), and Genome Canada. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative & quantitative information and assess the prospects of the market. Various primary sources from both the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Oligonucleotide Synthesis Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate & validate the total size of the oligonucleotide synthesis market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Oligonucleotide Synthesis Market

Data Triangulation

The total market was split into several segments and subsegments after arriving at the overall market size from the estimation process. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Oligonucleotide synthesis is the chemical process of creating nucleic acid fragments with specific chemical structures or sequences of varying sizes to form a desired product. These fragments, known as oligonucleotides, have several applications in medical & life science research. They can be used for DNA sequencing and amplification, detecting complementary DNA or RNA through hybridization, creating artificial genes, and introducing targeted genetic mutations.

Oligonucleotides are also used to develop therapeutic drugs. These drugs are produced chemically and have different mechanisms of action, such as interfering with gene expression, blocking the production of harmful proteins, or restoring the function of mutated genes.

Stakeholders

  • Pharmaceutical & biotechnology companies
  • Hospitals
  • Diagnostic laboratories
  • Academic researchers and government research organizations
  • Private research institutes
  • Custom oligonucleotide service providers
  • Contract manufacturing organizations (CMOs)
  • Oligonucleotide equipment manufacturers
  • Contract research organizations (CROs)
  • Market research & consulting firms
  • Venture capitalists

Report Objectives

  • To define, describe, and forecast the global oligonucleotide synthesis market based on the product, application, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oligonucleotide synthesis market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • Track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the oligonucleotide synthesis market.
  • To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the oligonucleotide synthesis market.

 

TABLE OF CONTENTS

METHODOLOGY

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Oligonucleotide Synthesis Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Oligonucleotide Synthesis Market

DMCA.com Protection Status